Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects
Diabetes · 2024
DOI: 10.2337/db23-0457 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, 2024. Verfasst von Xi Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Kidney, Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, Astra Zeneca.
Abstract (Originalsprache)
Acute and chronic sodium–glucose cotransporter 2 (SGLT-2) inhibition increases endogenous glucose production (EGP). However, the organ—liver versus kidney—responsible for the increase in EGP has not been identified. In this study, 20 subjects with type 2 diabetes (T2D) and 12 subjects with normal glucose tolerance (NGT) received [3-3H]glucose infusion (to measure total EGP) combined with arterial and renal vein catheterization and para-aminohippuric acid infusion for determination of renal blood flow. Total EGP, net renal arteriovenous balance, and renal glucose production were measured before and 4 h after dapagliflozin (DAPA) and placebo administration. Following DAPA, EGP increased in both T2D and NGT from baseline to 240 min, while there was a significant time-related decrease after placebo in T2D. Renal glucose production at baseline was <5% of basal EGP in both groups and did not change significantly following DAPA in NGT or T2D. Renal glucose uptake (sum of tissue glucose uptake plus glucosuria) increased in both T2D and NGT following DAPA (P < 0.05 vs. placebo). The increase in renal glucose uptake was entirely explained by the increase in glucosuria. A single dose of DAPA significantly increased EGP, which primarily is explained by an increase in hepatic glucose production, establishing the existence of a novel renal-hepatic axis. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX.
- Audie L. Murphy Memorial Veterans' Hospital, South Texas Veterans Affairs Heath Care System, San Antonio, TX.
ORCID-Profile: Devjit Tripathy, Carolina Solis-Herrera, Eugenio Cersosimo, Ralph A DeFronzo
Förderung
- NIDDK NIH HHS
- NIH HHS
- Astra Zeneca
- National Institutes of Health
Zitieren
APA
Chen, X., Tripathy, D., Chilton, R., Hansis-Diarte, A., Salehi, M., Solis-Herrera, C., Cersosimo, E., & DeFronzo, R. A. (2024). Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects. Diabetes. https://doi.org/10.2337/db23-0457
Vancouver
Chen X, Tripathy D, Chilton R, Hansis-Diarte A, Salehi M, Solis-Herrera C, et al. Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects. Diabetes. 2024. doi:10.2337/db23-0457
BibTeX
@article{Chen2024,
author = {Chen, Xi and Tripathy, Devjit and Chilton, Robert and Hansis-Diarte, Andrea and Salehi, Marzieh and Solis-Herrera, Carolina and Cersosimo, Eugenio and DeFronzo, Ralph A},
title = {Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects},
journal = {Diabetes},
year = {2024},
doi = {10.2337/db23-0457}
}
EUVIMED